Menu
Back to Journals » OncoTargets and Therapy » Volume 14
RETRACTED ARTICLE: Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer
Authors Yu J , Sun S, Mao W, Xu B, Chen M
Received 10 March 2021
Accepted for publication 25 May 2021
Published 21 June 2021 Volume 2021:14 Pages 3833—3848
DOI https://doi.org/10.2147/OTT.S309917
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Gaetano Romano
This paper has been retracted.
Yu J, Sun S, Mao W, Xu B, Chen M. Onco Targets Ther. 2021;14:3833–3848.
We, the Editor and Publisher of OncoTargets and Therapy are retracting the published article. Since publication, concerns have been raised about the integrity of the data in the article and it was found some of the images had been duplicated. Specifically,
- Images from Figure 8G, Invasion and Migration, LNcap, si-NC, appear to have been duplicated.
When approached for an explanation, the authors were cooperative but were unable to adequately address the concerns raised and have not been able to provide sufficient supporting information from their study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.